Sarepta Therapeutics Inc. (NASDAQ:SRPT) traded down 1.1% during mid-day trading on Monday . The company traded as low as $22.10 and last traded at $22.37, with a volume of 1,803,961 shares trading hands. The stock had previously closed at $22.62.

A number of equities research analysts have recently issued reports on the company. JMP Securities reiterated a “sell” rating and issued a $10.00 target price on shares of Sarepta Therapeutics in a research note on Friday, June 3rd. Vetr upgraded Sarepta Therapeutics from a “strong sell” rating to a “hold” rating and set a $11.60 target price for the company in a research note on Wednesday, April 27th. Janney Montgomery Scott reiterated a “hold” rating on shares of Sarepta Therapeutics in a research note on Tuesday, June 7th. Cowen and Company reiterated a “hold” rating on shares of Sarepta Therapeutics in a research note on Tuesday, June 7th. Finally, Robert W. Baird reiterated a “buy” rating on shares of Sarepta Therapeutics in a research note on Sunday, May 8th. Five research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $24.17.

The firm’s market cap is $967.34 million. The company’s 50 day moving average is $19.31 and its 200-day moving average is $18.75.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Thursday, May 5th. The company reported ($1.15) EPS for the quarter, topping analysts’ consensus estimates of ($1.30) by $0.15. During the same period in the prior year, the business earned ($1.15) earnings per share. On average, equities analysts anticipate that Sarepta Therapeutics Inc. will post ($4.48) earnings per share for the current year.

A number of large investors have recently added to or reduced their stakes in the company. Nationwide Fund Advisors increased its stake in Sarepta Therapeutics by 9.2% in the fourth quarter. Nationwide Fund Advisors now owns 29,223 shares of the company’s stock worth $1,127,000 after buying an additional 2,471 shares during the period. ProShare Advisors LLC increased its stake in Sarepta Therapeutics by 20.5% in the fourth quarter. ProShare Advisors LLC now owns 42,922 shares of the company’s stock worth $1,656,000 after buying an additional 7,301 shares during the period. New York State Common Retirement Fund increased its stake in Sarepta Therapeutics by 13.5% in the fourth quarter. New York State Common Retirement Fund now owns 44,700 shares of the company’s stock worth $1,725,000 after buying an additional 5,300 shares during the period. Rhumbline Advisers increased its stake in Sarepta Therapeutics by 16.1% in the fourth quarter. Rhumbline Advisers now owns 47,728 shares of the company’s stock worth $1,841,000 after buying an additional 6,615 shares during the period. Finally, Creative Planning increased its stake in Sarepta Therapeutics by 95.7% in the fourth quarter. Creative Planning now owns 52,950 shares of the company’s stock worth $2,043,000 after buying an additional 25,900 shares during the period.

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.